Long-term extension trial results with donanemab suggest a widening separation in cognitive decline through 36 months in early Alzheimer’s disease.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/therapeutic-research-alzheimers-disease-what-new-2026a10006bo?src=rss
Author :
Publish date : 2026-03-02 10:05:00
Copyright for syndicated content belongs to the linked Source.